阿柏西普凭借更好的疗效和依从性，逆袭罗氏旗下基因泰克和诺华联合开发的雷珠单抗。而有了被超越的经历后，罗氏从临床需求、痛点出发，瞄准下一代抗VEGF眼科药物的机会。

The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be fully ...

Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.

眼科药王阿柏西普（Eylea）再受打击。 自2015年销售额反超雷珠单抗（Lucentis）以来，阿柏西普一直统治着整个眼科抗VEGF药物市场，且常年霸榜全球 ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

但「湿性」患者则可靠注射「血管内皮生长因子抑制剂」（Anti-VEGF，常见的药物有三种：Avastin、Lucentis、Eylea，还有一种为长效型类固醇Ozurdex ...

如心衰爆款药物Entresto（60亿美元）、IL-17A单抗Cosentyx（50亿美元）、IgE单抗Xolair（36亿美元），Revolade、Kesimpta、Kisqali、Lucentis、Tafinlar、Tasigna的营收 ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

The products—ReoPro, Lucentis and Cimzia—are used as treatments for cardiovascular, ophthalmic and immunological indications, respectively (Table 1). All three approved products are Fab molecules.

For example, in the UK, the National Institute for Health and Clinical Excellence (NICE) would only reimburse the use of Lucentis [ranibizumab, a humanized monoclonal antibody fragment that binds ...